Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?
Tyra Biosciences, Inc. (TYRA) is positioned as a promising biotech stock due to upcoming clinical milestones, particularly the anticipated complete response data from its SURF302 study in August 2026. Oppenheimer initiated coverage with an "Outperform" rating and a $50 price target, citing the company's strong cash position and oral treatment approach. Despite reporting a net loss in Q1 2026 due to increased R&D expenses, analysts are optimistic about TYRA's potential in precision medicine for cancer.
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2500 Growth Benchmark
Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth Benchmark and Russell 3000E Growth Benchmark. Concurrently, the company was dropped from several other Russell benchmarks, including the Russell Small Cap Comp Value Benchmark, Russell Microcap Index, Russell 3000 Value Benchmark, and Russell 2500 Value Benchmark. Tyra Biosciences is a clinical-stage biotechnology company focused on developing precision medicines targeting FGFR biology.
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Growth Benchmark
Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 2000 Growth Benchmark. This news comes alongside other recent index adjustments, including being dropped from several Russell Value and Microcap indices, but added to the Russell 3000E Growth Benchmark. The company is a clinical-stage biotechnology firm focused on developing precision medicines targeting FGFR biology.
(TYRA) Movement Within Algorithmic Entry Frameworks
The article provides an algorithmic analysis of Tyra Biosciences Inc. (NASDAQ: TYRA), indicating strong sentiment across all time horizons supporting an overweight bias. It outlines detailed institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry zones, targets, and stop losses. The analysis also highlights elevated downside risk due to a lack of additional long-term support signals.
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell Microcap Index
Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been removed from the Russell Microcap Index. This follows earlier reports of its exclusion from the Russell 3000 Value Benchmark and the Russell 2500 Value Benchmark. The company, a clinical-stage biotechnology firm, focuses on developing precision medicines targeting FGFR biology.
10 Most Promising Cancer Stocks According to Wall Street Analysts
This article identifies Tyra Biosciences, Inc. (NASDAQ:TYRA) as one of the most promising cancer stocks, citing an Outperform rating and $50 price target from Oppenheimer. The firm's confidence is based on upcoming clinical milestones, particularly full response data from the SURF302 study, and the company's strong cash position. Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines for cancer.
Form 144 | TYRA BIOSCIENCES, INC.(TYRA.US) Insider Proposes to Sell 9.54 Million in Common Stocks
An insider at TYRA BIOSCIENCES, INC. (TYRA.US) has filed a Form 144 proposing to sell common stocks valued at $9.54 million. The filing indicates a significant potential transaction by an insider of the company.
Form 144 TYRA BIOSCIENCES For: 26 June By Investing.com
This article announces that TYRA Biosciences has filed a Form 144 for June 26. A Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article provides only this brief detail and is published by Investing.com.
TYRA (NASDAQ: TYRA) sells common shares under Rule 144 in June 2026
NEXTECH VI ONCOLOGY SCSP reported four sales of TYRA (NASDAQ: TYRA) common stock in June 2026 under a Rule 144 notice, with transactions occurring on June 1, 23, 24, and 25. The sales were handled by Merrill Lynch, generating total proceeds exceeding $4 million. The filing provides details on the number of shares and gross proceeds for each trade, indicating a neutral impact and sentiment according to Rhea-AI Filing Summary.
Tyra Bioscience, Inc Actuals & Estimates (NASDAQ:TYRA)
This article provides an overview of Tyra Biosciences, Inc. (NASDAQ:TYRA) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, earnings per share, revenue, and market capitalization. The company's upcoming earnings report date and employee count are also mentioned.
TYRA Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Tyra Biosciences, Inc. (TYRA) stock, including analyst ratings, historical performance, and future earning estimates. It details the company's financial status, market capitalization, and upcoming earnings report. The piece also addresses frequently asked questions about TYRA's stock price, volatility, and recommendations for potential investors.
Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In?
Tyra Biosciences (TYRA) has gained attention due to recent positive Phase II results for its experimental therapy Dabogratinib, used for non-muscle invasive bladder cancer. While short-term stock momentum has cooled, long-term investors have seen significant gains. The article discusses whether the current stock valuation and analyst targets fully price in future growth, noting its premium P/B ratio compared to the broader US biotech industry but good value compared to closer peers, while also highlighting risks such as its lack of revenue and ongoing net loss.
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Tyra Biosciences Inc (TYRA), focusing on support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, KDJ, and ATR, along with their values and directional signals. The analysis concludes with a "Buy" signal based on moving averages and other technical indicators, despite some mixed individual indicator signals.
Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Tyra Bioscience (TYRA)
This article highlights bullish sentiments from analysts on several healthcare stocks. ClearPoint Neuro (CLPT) received a Buy rating with a $30 price target, and a Strong Buy consensus, while Tyra Bioscience (TYRA) also got a Buy rating and a $50 price target, with a Strong Buy consensus. Connect Biopharma Holdings (CNTB) was rated Buy with a $6 price target and a Strong Buy consensus, indicating significant upside potential for these companies.
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50
Oppenheimer has reiterated its Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US) and maintained its price target at $50. This continued endorsement by the firm suggests a positive outlook on the company's future performance and valuation. Investors may use this information as part of their due diligence for TYRA stock.
Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Tyra Biosciences Inc (TYRA), listing its major shareholders by proportion as well as a breakdown of shareholder types, including venture capital, hedge funds, and individual investors. It also provides institutional shareholding data over several quarters and recent shareholder activity with changes in holdings for key institutions. The information highlights the significant institutional interest and ownership profile of the company.
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Tyra Biosciences Inc (TYRA) regarding its dividend history and stock splits. It states that no dividends have been distributed over the past five years and no stock split data is available. The article serves as a record of financial events for the company on TradingKey.
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Tyra Biosciences Inc (TYRA), detailing analyst ratings, price targets, and EPS estimates. Based on 15 analysts, the stock has a "Buy" consensus rating with a target price of USD 31.00, suggesting an 81.75% upside. The company's previous quarter EPS was USD -2.01 against an expectation of USD -0.64, with the next quarter's EPS projected at USD -0.65.
TYRA Initiated Coverage by Jones Trading -- Rating Set to Buy
Jones Trading initiated coverage on Tyra Biosciences (TYRA) with a Buy rating and a $56.00 price target. This positive outlook is supported by endorsements from other analysts, although the company's GF Score™ of 30 and recent insider selling activity suggest potential risks that investors should consider. Tyra Biosciences is a clinical-stage biotechnology company focused on oncology and genetically defined conditions.
Tyra Biosciences Inc (TYRA) Institutional Confidence
This article from TradingKey provides an overview of institutional confidence in Tyra Biosciences Inc (TYRA). It lists the institutional shareholders and their shareholdings, highlighting changes in their positions. The primary focus is on the "Institutional Shareholding" and "Shareholder Activity" data for TYRA.
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says
BofA Securities reiterated its Underperform rating and $3 price target for Tyra Biosciences, noting weak investor sentiment due to macro pressures and renewed concerns about the SURF-302 program's competitive landscape. The analyst highlights that despite the unmet need in HR+ /HER2- mBC with activating FGFR2 mutations, the presence of multiple competitors implies a limited window for Tyra to achieve a competitive profile. This outlook suggests challenges for the company's stock performance.
Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity
The Urothelial Carcinoma market is projected for significant expansion by 2036, driven by an increasing incidence of bladder cancer, advancements in immunotherapies and targeted therapies, and a strong pipeline of novel drugs. Key players like Bristol-Myers Squibb, Astellas Pharma, and Pfizer are developing and launching new treatments. DelveInsight's report details market trends, epidemiology, and pipeline activities across major global markets.
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42
BofA Securities has reiterated its Buy rating for TYRA Biosciences, Inc. (TYRA.US) and increased the price target to $42. This sustained positive outlook from the financial firm indicates confidence in the company's future performance. The raised target price suggests an expectation of significant growth for TYRA Biosciences.
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59
Barclays analyst Eliana Merle has reiterated a Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) and maintained a target price of $59. According to TipRanks, Merle has a 36.8% success rate and a 1.4% average return over the past year. This rating indicates a continued positive outlook on the company's stock performance.
TYRA Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Tyra Biosciences Inc (TYRA), detailing its revenue streams, profitability, and comparative metrics against competitors like TSHA and SION. While specific gross, operating, and net margins are N/A, the company shows a Return on Equity (ROE) of -36.87%. TYRA has a market capitalization of $1.58B, positioning it significantly within its sector.
TYRA - Tyra Biosciences Inc Stock Price and Quote
This article provides a comprehensive overview of Tyra Biosciences Inc (TYRA) stock, including its latest price, financial metrics, insider transactions, and analyst ratings. It details the company's focus on precision oncology and its pipeline of selective inhibitors, along with recent news and investor conference participations.
TYRA: Dabogratinib advances in three FGFR3-driven indications, with pivotal data readouts ahead
Dabogratinib, developed by Tyra Biosciences, is progressing in late-stage clinical trials for three distinct FGFR3-driven indications. Key data readouts are anticipated in August for NMIBC, in Q4 for achondroplasia, and in 2027 for UTUC, with an oral administration offering a less invasive approach.
Tyra Biosciences (NASDAQ: TYRA) details 2026 shareholder meeting voting outcomes
Tyra Biosciences, Inc. (NASDAQ: TYRA) announced the results of its 2026 Annual Meeting of Stockholders held on May 28, 2026. Shareholders elected three directors—Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More—each receiving over 41 million votes. Additionally, a separate meeting proposal was overwhelmingly approved with 53,092,820 votes in favor.
Tyra Biosciences (TYRA) director granted 13,160 stock options
Tyra Biosciences director Stephen Michael Rothenberg was granted 13,160 stock options with an exercise price of $32.68 per share, expiring on May 27, 2036. This grant is part of the company's Non-Employee Director Compensation Program. The options will vest monthly over 12 installments, with a provision for earlier vesting at the next annual stockholder meeting under certain conditions.
Tyra Biosciences (TYRA) director option grant tied to RA Capital funds
Tyra Biosciences reported a Form 4 detailing a grant of 13,160 stock options to non-employee director Jake Simson, with an exercise price of $32.68 per share. The options, granted under the company's Non-Employee Director Compensation Program, are held for the benefit of RA Capital-managed entities. Mr. Simson is obligated to remit any net cash or stock from exercising these options to RA Capital Management to offset advisory fees.
Tyra Biosciences (TYRA) director option grant held for RA Capital funds
Tyra Biosciences, Inc. reported a Form 4 detailing a stock option grant of 13,160 shares to director Jake Simson, as part of the company's Non-Employee Director Compensation Program. The option has an exercise price of $32.68 and vests monthly after May 28, 2026. However, Simson disclaims beneficial ownership as the option is held for the benefit of RA Capital funds, with any proceeds offsetting advisory fees.
[144] Tyra Biosciences, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Tyra Biosciences, Inc. (TYRA) related to the proposed sale of securities, indicating a neutral filing impact and sentiment. The filing details the sale of 300,000 common shares with an aggregate market value of $10,023,000, acquired via private placement in 2021, and includes the filer and issuer information, as well as the name of the broker. The document also provides a snapshot of recent news, SEC filings, and stock data for Tyra Biosciences.
Director at Tyra Biosciences (NASDAQ: TYRA) awarded stock options
Tyra Biosciences director Robert J. More was granted stock options for 13,160 shares of common stock at an exercise price of $32.68 per share. The options expire on May 27, 2036, and vest in 12 equal monthly installments starting May 28, 2026, with full vesting possibly accelerated to the next annual stockholder meeting under certain conditions. This grant is part of the company's Non-Employee Director Compensation Program.
Tyra Biosciences (TYRA) director granted 13,160 stock options at $32.68
Tyra Biosciences director Susan Moran was granted 13,160 stock options with an exercise price of $32.68 per share as part of the company's Non-Employee Director Compensation Program. These options will vest monthly over a year, with accelerated vesting if the next annual stockholder meeting occurs earlier, provided she maintains continuous service. Following this grant, Moran directly holds 13,160 options.
Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)
Wolfe Research initiated coverage on Tyra Biosciences, Inc. (TYRA) with a Peer Perform rating, citing the potential of its drug dabogratinib for bladder cancer but expressing caution pending safety data. Tyra Biosciences recently reported a Q1 net loss of $39.3 million and increased R&D expenses, with $383.5 million in cash expected to fund operations into late 2028. The company is advancing its "dabogratinib 3x3" strategy and expects multiple data readouts in 2026.
What's Driving Tyra Biosciences' Recent Surge
Tyra Biosciences (TYRA) has seen a recent surge due to promising data for its lead candidate, dabogratinib, presented at the 2026 ASCO GU Cancers Symposium. The company's proprietary SNÅP platform and diversified pipeline targeting FGFR biology position it as a leader in precision oncology and genetically defined conditions. Despite positive analyst sentiment and significant market opportunities, Tyra faces inherent risks associated with clinical development and competitive pressures in the biotech sector.
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing
The article analyzes Tyra Biosciences Inc. (TYRA) stock, highlighting weak near-term sentiment but strong long-term potential. It presents institutional trading strategies, including long, momentum breakout, and short options, based on AI-generated signals and multi-timeframe analysis. The analysis emphasizes a significant risk-reward setup targeting a 15.3% gain against a 0.3% risk.
This Tyra Biosciences Insider Reduced Their Stake By 58%
This article reports on a significant reduction in a Tyra Biosciences insider's stake, with their ownership decreasing by 58%. Such insider selling can sometimes signal a lack of confidence in the company's future prospects, though more context would be needed to draw definitive conclusions.
Tyra Biosciences, Inc. Stock 12‑Month Price Target Raised to $51.78, Implies 59% Upside
Tyra Biosciences, Inc.'s average 12-month stock price target has been increased to $51.78 from $50.3, based on estimates from 9 analysts, with individual forecasts ranging from $44 to $59 per share. This new target suggests a potential upside of approximately 59% from its May 22 closing price. The consensus rating for the stock remains "Buy" among 13 analysts, underscoring strong confidence in its future performance.
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating
William Blair has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US). The report indicates continued confidence in the company's prospects.
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
Tyra Biosciences and the Bladder Cancer Advocacy Network (BCAN) have partnered to designate May 21 as Upper Tract Urothelial Cancer (UTUC) Awareness Day. This initiative aims to increase awareness, amplify patient voices, and highlight the need for research and innovation in treating UTUC, a rare and difficult-to-treat cancer with limited effective options. Tyra Biosciences is currently developing dabogratinib, an investigational oral FGFR3-selective inhibitor, as a potential kidney-sparing treatment for low-grade UTUC.
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
Tyra Biosciences and the Bladder Cancer Advocacy Network (BCAN) have partnered to establish May 21st as Upper Tract Urothelial Cancer (UTUC) Awareness Day. This initiative aims to increase awareness, amplify patient experiences, and encourage research into UTUC, a rare and difficult-to-treat cancer with limited systemic standard of care. Tyra Biosciences is currently developing dabogratinib, an investigational oral FGFR3-selective inhibitor, as a potential kidney-sparing treatment for low-grade UTUC.
Assessing Tyra Biosciences (TYRA) Valuation After Wider Losses And Progress In Dabogratinib Trials
Tyra Biosciences (TYRA) is under scrutiny after reporting wider losses but showing progress in its dabogratinib trials and attracting new institutional interest. Despite recent stock dips, TYRA has seen significant year-to-date and one-year returns, driven by its pipeline. The company trades at a Price-to-Book ratio of 5.2x, which is high compared to the broader US biotech industry but lower than its direct peers, suggesting a premium on its drug pipeline and cash.
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation
Wolfe Research has initiated coverage on Tyra Biosciences (TYRA) with a "peer perform" recommendation. This suggests that the firm expects Tyra Biosciences to perform in line with its industry peers.
Wolfe Research Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Hold Rating
Wolfe Research has initiated coverage on TYRA BIOSCIENCES, INC. (TYRA.US) with a "Hold" rating. This indicates that the firm views the stock as adequately valued at its current price and advises investors to maintain their existing positions.
TYRA Initiates Coverage On Wolfe Research -- Rating Set to Peer Perform
Wolfe Research has initiated coverage of Tyra Biosciences (TYRA) with a "Peer Perform" rating, indicating expectations for its stock to perform in line with its industry peers. No price target has been set, reflecting potential uncertainties. The company, a clinical-stage biotechnology firm with a $2.12 billion market cap, has a GF Score of 30/100, highlighting strong financial health but weaknesses in profitability and growth.
Wolfe Research initiates Tyra Biosciences stock at Peerperform By Investing.com
Wolfe Research initiated coverage on Tyra Biosciences (NASDAQ:TYRA) with a Peerperform rating, focusing on its selective FGFR3 inhibitor for bladder cancer and achondroplasia. The firm anticipates dabogratinib could achieve significant complete response rates for bladder cancer and contribute to revenue by 2029. Despite the stock appearing overvalued relative to its Fair Value, the company boasts a strong balance sheet with high liquidity, and analysts largely maintain a Strong Buy consensus.
Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile?
Tyra Biosciences (TYRA) reported a wider net loss of US$39.31 million in Q1 2026, with a basic loss per share of US$0.64. However, the company highlighted progress in three Phase 2 trials for its lead candidate, dabogratinib, and a strong cash balance of US$383.5 million, providing a runway into the second half of 2028. This focused "dabogratinib 3x3" strategy, targeting three FGFR3-driven indications, is central to the company's investment narrative, with upcoming clinical readouts serving as key catalysts, though the stock's valuation remains a point of exploration for investors.
Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile?
Tyra Biosciences reported a wider net loss of US$39.31 million in Q1 2026 but highlighted progress in three Phase 2 trials for its lead candidate, dabogratinib, and a cash balance of US$383.5 million to fund operations into mid-2028. The company's "dabogratinib 3x3" strategy focuses resources on three FGFR3-driven indications, which management believes will shape its path towards drug registration and commercialization. While the long cash runway and rising losses have implications, the stock currently has only one fair value estimate from the Simply Wall St Community.
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences announced its Q1 2026 financial results, highlighting significant progress in its "dabogratinib 3x3" strategy. The company initiated a late-stage clinical study (SURF303) for LG-UTUC, with initial results expected in 2027, and anticipates data readouts for IR NMIBC and achondroplasia programs in August and Q4 2026, respectively. Tyra Biosciences also reported a strong financial position with $383.5 million in cash, cash equivalents, and marketable securities, providing a runway into the second half of 2028.
